In summary, in addition to affecting the proliferation of tumor cells themselves, cancer cell‐intrinsic SMYD3 shapes the immunosuppressive microenvironment by altering the landscape of immune cell infiltration, thus impairing the efficacy of ICI therapy (PD‐1 blockade). Here, SMYD3 is linked to cancer.